Measure of ⁹⁰Y-glass microspheres residue post-TARE using PET/CT and potential impact on tumor absorbed dose in comparison ^99mTc-MAA SPECT/CT dosimetry.

EJNMMI reports Pub Date : 2024-08-26 DOI:10.1186/s41824-024-00214-8

Sarah Boughdad, Rafael Duran, John O Prior, Michael da Mota, Mélanie Mendes De Carvalho, Julien Costes, Maria Firsova, Silvano Gnesin, Niklaus Schaefer

{"title":"Measure of 90Y-glass microspheres residue post-TARE using PET/CT and potential impact on tumor absorbed dose in comparison 99mTc-MAA SPECT/CT dosimetry.","authors":"Sarah Boughdad, Rafael Duran, John O Prior, Michael da Mota, Mélanie Mendes De Carvalho, Julien Costes, Maria Firsova, Silvano Gnesin, Niklaus Schaefer","doi":"10.1186/s41824-024-00214-8","DOIUrl":null,"url":null,"abstract":"Background: Transarterial radio-embolization (TARE) became a routine procedure for non-resectable liver tumor mainly hepatocellular carcinoma (HCC). Personalized dosimetry to the index lesion increased tumor response rate. However, there is no requirement to measure the precise activity injected during TARE. We measured 90Y-glass microspheres residue (90Y-Res) in the application system after TARE and assessed its potential impact on the tumor absorbed dose (AD) previously planned with 99mTc MAA SPECT/CT.Methods: We measured 90Y-Res using PET/CT in all patients that underwent TARE using 90Y-glass-microspheres for non-resectable liver tumors over one year.Results: 90Y-Res was measured in 34 patients (HCC n = 22) with 61 injections, 93.1 ± 94.6 MBq [2-437] that was 4.8 ± 3.5% [0.2-13.7] in comparison to the activity measured in the sealed TheraSphere™ vial (ρ = 0.697; p < 0.001).Conclusion: We reported an average of 5% 90Y-Res using PET/CT after TARE with the strongest association to the activity in the TheraSphere™ vial. Therefore, when a high 90Y-Res is suspected on the survey meter, a 90Y-PET/CT scan of 90Y-Res might be useful as a first step to estimate if the target lesion received the recommended AD, especially in HCC patients with borderline tumor dosimetry on the pre-treatment 99mTc-MAA SPECT/CT.","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"8 1","pages":"26"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11345342/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJNMMI reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s41824-024-00214-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Transarterial radio-embolization (TARE) became a routine procedure for non-resectable liver tumor mainly hepatocellular carcinoma (HCC). Personalized dosimetry to the index lesion increased tumor response rate. However, there is no requirement to measure the precise activity injected during TARE. We measured ⁹⁰Y-glass microspheres residue (⁹⁰Y-Res) in the application system after TARE and assessed its potential impact on the tumor absorbed dose (AD) previously planned with ^99mTc MAA SPECT/CT.

Methods: We measured ⁹⁰Y-Res using PET/CT in all patients that underwent TARE using ⁹⁰Y-glass-microspheres for non-resectable liver tumors over one year.

Results: ⁹⁰Y-Res was measured in 34 patients (HCC n = 22) with 61 injections, 93.1 ± 94.6 MBq [2-437] that was 4.8 ± 3.5% [0.2-13.7] in comparison to the activity measured in the sealed TheraSphere™ vial (ρ = 0.697; p < 0.001).

Conclusion: We reported an average of 5% ⁹⁰Y-Res using PET/CT after TARE with the strongest association to the activity in the TheraSphere™ vial. Therefore, when a high ⁹⁰Y-Res is suspected on the survey meter, a ⁹⁰Y-PET/CT scan of ⁹⁰Y-Res might be useful as a first step to estimate if the target lesion received the recommended AD, especially in HCC patients with borderline tumor dosimetry on the pre-treatment ^99mTc-MAA SPECT/CT.

查看原文本刊更多论文

使用 PET/CT 测量 TARE 后 90Y 玻璃微球的残留量，并比较 99mTc-MAA SPECT/CT 剂量测定对肿瘤吸收剂量的潜在影响。

背景：经动脉放射栓塞术（TARE）已成为治疗以肝细胞癌（HCC）为主的不可切除肝脏肿瘤的常规方法。针对指标病灶的个性化剂量测量提高了肿瘤反应率。然而，目前还没有对 TARE 期间注入的精确放射性活度进行测量的要求。我们测量了 TARE 后应用系统中的 90Y 玻璃微球残留物（90Y-Res），并评估了其对之前计划使用 99mTc MAA SPECT/CT 测量的肿瘤吸收剂量（AD）的潜在影响：我们使用 PET/CT 测量了一年内使用 90Y 玻璃微球进行 TARE 治疗不可切除肝脏肿瘤的所有患者的 90Y-Res：34例患者（HCC n = 22）共注射了61次90Y-Res，测量值为93.1 ± 94.6 MBq [2-437]，与密封的TheraSphere™小瓶中测量的活性相比，90Y-Res的测量值为4.8 ± 3.5% [0.2-13.7] (ρ = 0.697; p 结论：我们报告了 TARE 后 PET/CT 的 90Y-Res 平均值为 5%，与 TheraSphere™ 瓶中的活性关联最大。因此，当调查表怀疑 90Y-Res 偏高时，90Y-PET/CT 的 90Y-Res 扫描可能是估计靶病变是否接受了推荐 AD 的第一步，尤其是在治疗前 99mTc-MAA SPECT/CT 肿瘤剂量测定处于边缘的 HCC 患者中。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

EJNMMI reports

自引率

0.00%

发文量